About
Melodia Therapeutics develops a next-generation DPP1 inhibitor using a selective non-covalent nitrile-based mechanism to treat severe neutrophil-driven inflammatory diseases affecting respiratory, dermatologic, and systemic disorders.
Explore Melodia Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.